These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

174 related items for PubMed ID: 29957076

  • 1. Triptorelin depot for the treatment of children 2 years and older with central precocious puberty.
    Bertelloni S, Mucaria C, Baroncelli GI, Peroni D.
    Expert Rev Clin Pharmacol; 2018 Jul; 11(7):659-667. PubMed ID: 29957076
    [Abstract] [Full Text] [Related]

  • 2. Efficacy and safety of triptorelin 6-month formulation in patients with central precocious puberty.
    Klein K, Yang J, Aisenberg J, Wright N, Kaplowitz P, Lahlou N, Linares J, Lundström E, Purcea D, Cassorla F.
    J Pediatr Endocrinol Metab; 2016 Nov 01; 29(11):1241-1248. PubMed ID: 26887034
    [Abstract] [Full Text] [Related]

  • 3. Efficacy of Triptorelin 3-Month Depot Compared to 1-Month Depot for the Treatment of Korean Girls with Central Precocious Puberty in Single Tertiary Center.
    Chung LY, Kang E, Nam HK, Rhie YJ, Lee KH.
    J Korean Med Sci; 2021 Aug 30; 36(34):e219. PubMed ID: 34463062
    [Abstract] [Full Text] [Related]

  • 4. Treatment of central precocious puberty with triptorelin 11.25 mg depot formulation.
    Martínez-Aguayo A, Hernández MI, Beas F, Iñiguez G, Avila A, Sovino H, Bravo E, Cassorla F.
    J Pediatr Endocrinol Metab; 2006 Aug 30; 19(8):963-70. PubMed ID: 16995580
    [Abstract] [Full Text] [Related]

  • 5. Three-month sustained-release triptorelin (11.25 mg) in the treatment of central precocious puberty.
    Carel JC, Blumberg J, Seymour C, Adamsbaum C, Lahlou N, Triptorelin 3-month CPP Study Group.
    Eur J Endocrinol; 2006 Jan 30; 154(1):119-24. PubMed ID: 16382000
    [Abstract] [Full Text] [Related]

  • 6. Efficacy and Safety of Triptorelin 3-Month Formulation in Chinese Children with Central Precocious Puberty: A Phase 3, Open-Label, Single-Arm Study.
    Luo X, Zhang C, Yang Y, Xu X, Cheng X, Wei H, Wang L, Huang F, Shi X, Cabri P.
    Adv Ther; 2023 Oct 30; 40(10):4574-4588. PubMed ID: 37584898
    [Abstract] [Full Text] [Related]

  • 7. Central Precocious Puberty: Adult Height in Girls Treated with Quarterly or Monthly Gonadotropin-Releasing Hormone Analog Triptorelin.
    Bertelloni S, Massart F, Einaudi S, Wasniewska M, Miccoli M, Baroncelli GI.
    Horm Res Paediatr; 2015 Oct 30; 84(6):396-400. PubMed ID: 26528763
    [Abstract] [Full Text] [Related]

  • 8. Serum insulin-like growth factor I (IGF-I) and IGF-binding protein 3 levels are increased in central precocious puberty: effects of two different treatment regimens with gonadotropin-releasing hormone agonists, without or in combination with an antiandrogen (cyproterone acetate).
    Juul A, Scheike T, Nielsen CT, Krabbe S, Müller J, Skakkebaek NE.
    J Clin Endocrinol Metab; 1995 Oct 30; 80(10):3059-67. PubMed ID: 7559897
    [Abstract] [Full Text] [Related]

  • 9. Impact of 6-month triptorelin formulation on predicted adult height and basal gonadotropin levels in patients with central precocious puberty.
    Yoo E, Kim S, Jung HL, Shim JY, Shim JW, Kim DS, Kwak JH, Kim ES, Yang A.
    Front Endocrinol (Lausanne); 2023 Oct 30; 14():1134977. PubMed ID: 36875449
    [Abstract] [Full Text] [Related]

  • 10. Central precocious puberty: treatment with triptorelin 11.25 mg.
    Chiocca E, Dati E, Baroncelli GI, Cassio A, Wasniewska M, Galluzzi F, Einaudi S, Cappa M, Russo G, Bertelloni S.
    ScientificWorldJournal; 2012 Oct 30; 2012():583751. PubMed ID: 22645436
    [Abstract] [Full Text] [Related]

  • 11. Variations in pituitary-gonadal suppression during intranasal buserelin and intramuscular depot-triptorelin therapy for central precocious puberty. Belgian Study Group for Pediatric Endocrinology.
    Heinrichs C, Craen M, Vanderschueren-Lodeweyckx M, Malvaux P, Fawe L, Bourguignon JP.
    Acta Paediatr; 1994 Jun 30; 83(6):627-33. PubMed ID: 7919761
    [Abstract] [Full Text] [Related]

  • 12. Central precocious puberty: a single blood sample after gonadotropin-releasing hormone agonist administration in monitoring treatment.
    Salerno M, Di Maio S, Gasparini N, Mariano A, Macchia V, Tenore A.
    Horm Res; 1998 Jun 30; 50(4):205-11. PubMed ID: 9838241
    [Abstract] [Full Text] [Related]

  • 13. A 6-Month Trial of the Efficacy and Safety of Triptorelin Pamoate (11.25 mg) Every 3 Months in Children with Precocious Puberty: A Retrospective Comparison with Triptorelin Acetate.
    Zenaty D, Blumberg J, Liyanage N, Jacqz-Aigrain E, Lahlou N, Carel JC, Co-Investigators.
    Horm Res Paediatr; 2016 Jun 30; 86(3):188-195. PubMed ID: 27603324
    [Abstract] [Full Text] [Related]

  • 14. MANAGEMENT OF ENDOCRINE DISEASE: Long-term outcomes of the treatment of central precocious puberty.
    Guaraldi F, Beccuti G, Gori D, Ghizzoni L.
    Eur J Endocrinol; 2016 Mar 30; 174(3):R79-87. PubMed ID: 26466612
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Final height after long-term treatment with triptorelin slow release for central precocious puberty: importance of statural growth after interruption of treatment. French study group of Decapeptyl in Precocious Puberty.
    Carel JC, Roger M, Ispas S, Tondu F, Lahlou N, Blumberg J, Chaussain JL.
    J Clin Endocrinol Metab; 1999 Jun 30; 84(6):1973-8. PubMed ID: 10372696
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Meta-Analysis of Paediatric Patients with Central Precocious Puberty Treated with Intramuscular Triptorelin 11.25 mg 3-Month Prolonged-Release Formulation
.
    Durand A, Tauber M, Patel B, Dutailly P.
    Horm Res Paediatr; 2017 Jun 30; 87(4):224-232. PubMed ID: 28334719
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.